Acenocoumarol
Methimazole may decrease the anticoagulant activities of Acenocoumarol.
Acetyldigitoxin
The serum concentration of Acetyldigitoxin can be increased when it is combined with Methimazole.
AMBROXOL ACEFYLLINATE
The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methimazole.
Advertisement
Ambroxol-Theophylline-7-Acetate
The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methimazole.
Aminophylline
The serum concentration of Aminophylline can be increased when it is combined with Methimazole.
Artesunate
The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methimazole resulting in a loss in efficacy.
Advertisement
Atorvastatin
The risk or severity of adverse effects can be increased when Methimazole is combined with Atorvastatin.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Methimazole.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Methimazole.
Advertisement
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Methimazole.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Methimazole.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Methimazole.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Methimazole.
Clozapine
The risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine.
Deslanoside
The serum concentration of Deslanoside can be increased when it is combined with Methimazole.
Dicumarol
Methimazole may decrease the anticoagulant activities of Dicoumarol.
Digitoxin
The serum concentration of Digitoxin can be increased when it is combined with Methimazole.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Methimazole.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methimazole.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Methimazole.
Dyphylline
The serum concentration of Dyphylline can be increased when it is combined with Methimazole.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Methimazole.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Methimazole.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole.
Fluindione
Methimazole may decrease the anticoagulant activities of Fluindione.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Methimazole.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Methimazole.
iodide ion I-131
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Methimazole.
iodine I-131
The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Methimazole.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Methimazole.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Methimazole.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Methimazole.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methimazole.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Methimazole.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Methimazole.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Methimazole.
Ouabain
The serum concentration of Ouabain can be increased when it is combined with Methimazole.
Ovine Digoxin Immune Fab
The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Methimazole.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Methimazole.
Phenindione
Methimazole may decrease the anticoagulant activities of Phenindione.
Phenprocoumon
Methimazole may decrease the anticoagulant activities of Phenprocoumon.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Methimazole.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Methimazole.
Prednisolone
The serum concentration of Prednisolone can be decreased when it is combined with Methimazole.
Proscillaridin
The serum concentration of Proscillaridin can be increased when it is combined with Methimazole.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Methimazole.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Methimazole.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Methimazole.
Theophylline
The serum concentration of Theophylline can be increased when it is combined with Methimazole.
Theophylline anhydrous
The serum concentration of Theophylline can be increased when it is combined with Methimazole.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Methimazole.
Tizanidine
The serum concentration of Tizanidine can be increased when it is combined with Methimazole.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Methimazole.
Warfarin
Methimazole may decrease the anticoagulant activities of Warfarin.
